FDA Misbranding Action Clarification Sought By WLF In Appeals Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA should not be allowed to pursue a misbranding action based solely on the dissemination of information that complies with the district court's injunction in Washington Legal Foundation v. Henney permitting manufacturer-sponsored dissemination of peer-reviewed journal articles and medical texts, WLF argues in its Nov. 8 appellate brief.
You may also be interested in...
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.